The Choroideremia drugs in development market research report provides comprehensive information on the therapeutics under development for Choroideremia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Choroideremia. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Choroideremia - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Choroideremia and features dormant and discontinued products.

GlobalData tracks eight drugs in development for Choroideremia by eight companies/universities/institutes. The top development phase for Choroideremia is preclinical with four drugs in that stage. The Choroideremia pipeline has six drugs in development by companies and two by universities/ institutes. Some of the companies in the Choroideremia pipeline products market are: University of Pennsylvania, F. Hoffmann-La Roche and Curative Biotechnology.

The key targets in the Choroideremia pipeline products market include Rab Proteins Geranylgeranyltransferase Component A 1 (Choroideremia Protein or Rab Escort Protein 1 or TCD Protein or CHM), Retinoid Isomerohydrolase (All Trans Retinyl Palmitate Hydrolase or Retinal Pigment Epithelium Specific 65 kDa Protein or Retinol Isomerase or RPE65 or EC 3.1.1.64), and Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase (NADPH)] Kinase or AMPK or EC 2.7.11.31).

The key mechanisms of action in the Choroideremia pipeline product include Rab Proteins Geranylgeranyltransferase Component A 1 (Choroideremia Protein or Rab Escort Protein 1 or TCD Protein or CHM) Activator with three drugs in Phase II. The Choroideremia pipeline products include four routes of administration with the top ROA being Intravitreal and two key molecule types in the Choroideremia pipeline products market including Gene Therapy, and Small Molecule.

Choroideremia overview

Choroideremia is an X-linked chorioretinal dystrophy characterized by the diffuse, progressive degeneration of the retinal pigment epithelium (RPE), photoreceptors, and choriocapillaris. It is caused by a mutation in the CHM gene. Symptoms include night blindness, difficulty in peripheral vision, lack of visual acuity, and loss of ability to see colors. The diagnosis of choroideremia can be done by characteristic fundus findings and family history. It can be confirmed through direct genetic testing or by immunoblot analysis with anti-REP-1 antibody.

For a complete picture of Choroideremia’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.